PARP in Neurodegeneration

PARP in Neurodegeneration

Overview

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the transfer of ADP-ribose units to target proteins, forming poly(ADP-ribose) (PAR) polymers. While PARPs play essential roles in DNA repair, genome stability, and cell survival, their dysregulation has emerged as a critical mechanism in neurodegeneration. Overactivation of PARP1, the most studied member of this family, leads to catastrophic cellular energy depletion and triggers distinct forms of programmed cell death, including parthanatos[@andrabi2006].

The PARP family consists of 17 isoforms in humans, with PARP1, PARP2, and PARP5a/b being the most catalytically active. Among these, PARP1 accounts for the majority of cellular PARylation activity and is the primary mediator of pathological responses to DNA damage in neurons. Understanding PARP biology provides critical insights into neurodegenerative disease mechanisms and identifies potential therapeutic targets[@bock2021].

```mermaid
flowchart TD
subgraph TRIGGERS["Pathological Triggers"]
A1["DNA Damage<br/>(Oxidative Stress)"]
A2["Protein Aggregates<br/>(Abeta, alpha-Syn)"]
A3["Mitochondrial Toxins<br/>(MPTP, Rotenone)"]
A4["Excitotoxicity"]
end

subgraph PARP_PATHWAY["PARP1 Activation"]
B1["PARP1 Binds DNA Breaks"]
B2["Excessive PAR Synthesis"]
B3["NAD+ Depletion"]
B4["ATP Depletion"]
B5["AIF Translocation"]
end

PARP in Neurodegeneration

Overview

Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the transfer of ADP-ribose units to target proteins, forming poly(ADP-ribose) (PAR) polymers. While PARPs play essential roles in DNA repair, genome stability, and cell survival, their dysregulation has emerged as a critical mechanism in neurodegeneration. Overactivation of PARP1, the most studied member of this family, leads to catastrophic cellular energy depletion and triggers distinct forms of programmed cell death, including parthanatos[@andrabi2006].

The PARP family consists of 17 isoforms in humans, with PARP1, PARP2, and PARP5a/b being the most catalytically active. Among these, PARP1 accounts for the majority of cellular PARylation activity and is the primary mediator of pathological responses to DNA damage in neurons. Understanding PARP biology provides critical insights into neurodegenerative disease mechanisms and identifies potential therapeutic targets[@bock2021].

PARP Family Members

PARP1 (ARTD1)

PARP1 is the founding and most studied member of the PARP family:

• Size: 1014 amino acids, ~113 kDa
• Activation: DNA strand breaks activate PARP1's catalytic domain
• Domains: DNA-binding domain, automodification domain, catalytic domain
• Functions: DNA repair, chromatin remodeling, transcription regulation

PARP2 (ARTD2)

PARP2 shares functional redundancy with PARP1:

• Activation: Different DNA damage modalities than PARP1
• Compensation: PARP2 can partially compensate for PARP1 loss
• Unique functions: Involved in alternative DNA repair pathways

PARP5a/b (Tankyrases)

Tankyrases (PARP5a and PARP5b) have distinct functions:

• Wnt signaling: Regulates β-catenin degradation
• Telomere maintenance: Affects telomere length
• Neuronal functions: Emerging roles in synaptic plasticity

Molecular Mechanisms of PARP Activation

DNA Damage Sensing

PARP1 contains two zinc-finger domains that detect DNA breaks:

Upon DNA damage, PARP1 undergoes conformational changes that activate its catalytic domain, leading to PAR synthesis[@langelier2012].

PAR Synthesis

The catalytic reaction proceeds as follows:

Each PAR polymer contains 200+ ADP-ribose units, consuming equivalent NAD+ molecules. Under pathological conditions, this becomes catastrophic[@cohen2017].

PAR Turnover

PAR polymers are degraded by:

• PAR glycohydrolase (PARG): Primary PAR-degrading enzyme
• ADP-ribosylhydrolase 3 (ARH3): Mitochondrial PAR degradation
• Macrodomain-containing proteins: Alternative degradation pathways

PARP in Neurodegenerative Diseases

Parkinson's Disease

PARP activation is a significant contributor to dopaminergic neuron death in PD:

Mechanisms

• Mitochondrial toxins (MPTP, rotenone) trigger PARP activation
• α-Synuclein aggregation causes DNA damage
• Oxidative stress activates PARP via base excision repair
• PAR accumulation leads to AIF translocation

• Post-mortem PD brains show elevated PARP expression
• PARP1 knockout mice are protected from MPTP toxicity
• PARP inhibitors prevent dopaminergic neuron loss

• PARP inhibitors in clinical trials for PD
• Combined with L-DOPA for enhanced neuroprotection
• Targeting PARP1/PARP2 isoforms[@mandir2009]

Alzheimer's Disease

Multiple AD-related mechanisms trigger PARP activation:

Amyloid-β Induced PARP Activation

• Aβ causes oxidative DNA damage
• Direct interaction with PARP1
• Mitochondrial dysfunction leads to PARP hyperactivation

• Hyperphosphorylated tau impairs DNA repair
• PARP activation exacerbates tau pathology
• Circular relationship between PARP and tau

• PARP inhibitors reduce Aβ toxicity in models
• Combined targeting of PARP and tau may be synergistic
• NAD+ restoration strategies complement PARP inhibition[@kim2018]

Amyotrophic Lateral Sclerosis

PARP contributes to motor neuron death in ALS:

Oxidative Stress

• SOD1 mutations cause oxidative damage
• Chronic PARP activation depletes energy reserves

• Glutamate-induced calcium influx causes DNA damage
• PARP activation amplifies excitotoxic injury

• TDP-43 inclusions in ALS affect DNA repair
• PARP hyperactivation in TDP-43 models

Huntington's Disease

PARP activation contributes to striatal neuron death:

Mutant Huntingtin

• htt causes transcriptional dysfunction
• Impaired DNA repair mechanisms
• Increased sensitivity to oxidative stress

• Elevated PAR in HD models
• AIF-mediated cell death observed

PARP and Energy Metabolism

NAD+ Depletion

PARP hyperactivation creates a metabolic crisis:

One PAR polymer of 200 units consumes 200 NAD+ molecules, depleting cellular reserves within minutes of severe DNA damage[@berger1985].

Mitochondrial Effects

PARP activation affects mitochondria:

• AIF release: PAR triggers apoptosis-inducing factor translocation
• NAD+ loss: Mitochondrial NAD+ depleted
• Respiratory failure: Complex I activity reduced
• Permeability transition: MPTP opening

Therapeutic Strategies

PARP Inhibitors

• Prevent PAR synthesis and NAD+ depletion
• FDA-approved for cancer, repurposing for neurodegeneration
• Brain-penetrant options under development

• Nicotinamide riboside (NR)
• Nicotinamide mononucleotide (NMN)
• Direct NAD+ supplementation

PARP and Neuroinflammation

Microglial Activation

PARP regulates microglial responses:

• PARP1 deficiency reduces microglial activation
• PAR affects inflammatory gene expression
• NAD+ depletion limits inflammatory responses

Inflammatory Cytokines

PARP activation influences cytokine production:

• IL-1β, TNF-α expression modulated by PARP
• PAR polymers act as inflammatory signals
• PARP inhibition reduces neuroinflammation

Therapeutic Implications

PARP-based anti-inflammatory strategies:

• PARP inhibitors reduce microglial activation
• Combined anti-inflammatory and neuroprotective approaches
• Targeting PARP1 in neuroinflammation[@kauppinen2007]

Genetic Factors

PARP1 Polymorphisms

Genetic variants affect PARP activity:

• PARP1 Val762Ala affects catalytic activity
• Variants associated with cancer risk
• Potential implications for neurodegeneration

PARP2 and PARP5a

Emerging understanding of other PARPs:

• PARP2 mutations cause neurological symptoms
• Tankyrases in synaptic function
• PARP5a/b in neuronal development

Therapeutic Targeting

PARP Inhibitors

First-generation

• Nicotinamide: Weak PARP inhibitor
• 3-aminobenzamide: Experimental compound

• Olaparib: FDA-approved for cancer
• Rucaparib: Clinical use in oncology

• Veliparib: Brain-penetrant
• PJ34: Experimental, high potency

Clinical Trials

| Drug | Status | Indication | Notes |
|------|--------|------------|-------|
| Olaparib | Phase 2 | PD | Ongoing |
| Veliparib | Phase 2 | Stroke | Completed |
| Rucaparib | Preclinical | AD | Research |

Combination Strategies

• PARP inhibitors + NAD+ precursors
• PARP inhibitors + antioxidants
• PARP inhibitors + anti-inflammatory agents

Biomarkers

PAR Levels

• PAR in cerebrospinal fluid
• Blood PAR as peripheral marker
• PAR polymer detection methods

DNA Damage Markers

• 8-OHdG in urine and CSF
• Comet assay for peripheral cells
• γH2AX as DNA damage marker

NAD+ Metabolomics

• NAD+ / NADH ratio
• NMN and NR levels
• Metabolomic signatures

Cross-Links

• [PARP1](/proteins/parp1-protein) - Primary PARP in neurodegeneration
• [Parthanatos](/mechanisms/parthanatos) - PARP-mediated cell death
• [AIF](/proteins/aif-apoptosis-inducing-factor) - Effector molecule
• [NAD+](/biochemistry/nad-plus) - Depleted by PARP activation
• [Parkinson's Disease](/diseases/parkinsons-disease) - PARP in dopaminergic death
• [Alzheimer's Disease](/diseases/alzheimers-disease) - PARP in AD
• [DNA Repair](/mechanisms/dna-repair) - PARP's normal function
• [Oxidative Stress](/mechanisms/oxidative-stress) - Triggers PARP activation
• [Neuroinflammation](/mechanisms/neuroinflammation) - PARP in inflammation
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) - PARP's effect on mitochondria

See Also

• [PARP1](/proteins/parp1-protein)
• [Parthanatos](/mechanisms/parthanatos)
• [AIF](/proteins/aif-apoptosis-inducing-factor)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [DNA Repair](/mechanisms/dna-repair)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)